Protara Therapeutics (TARA) Capital Expenditures (2013 - 2025)

Protara Therapeutics' Capital Expenditures history runs 13 years deep, the most recent figure standing at $24000.0 for Q4 2025.

• In Q4 2025, Capital Expenditures changed N/A year-over-year to $24000.0; the TTM figure through Dec 2025 stood at $94000.0 (up 108.89% YoY), while the FY2025 annual figure was $94000.0, up 49.21% from the prior year.
• Capital Expenditures was $24000.0 for Q4 2025 at Protara Therapeutics, up from $4000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $326000.0 in Q2 2021 to a low of -$64000.0 in Q3 2021.
• Historically, Capital Expenditures has averaged $53937.5 across 5 years, with a median of $21000.0 in 2022.
• Biggest YoY gain for Capital Expenditures was 5533.33% in 2021; the steepest drop was 148.48% in 2021.
• A 5-year view of Capital Expenditures shows it stood at $44000.0 in 2021, then slumped by 86.36% to $6000.0 in 2022, then soared by 516.67% to $37000.0 in 2023, then slumped by 78.38% to $8000.0 in 2024, then soared by 200.0% to $24000.0 in 2025.
• The last three Capital Expenditures figures came in at $24000.0 (Q4 2025), $4000.0 (Q3 2025), and $22000.0 (Q2 2025), per Business Quant data.